Aktiechat - investeringstips
Aktiesnakken
Genmab
TESLA
Zealand Pharma
NOVO
Bavarian Nordic
Ennogie
Vestas
Pharma
Biotek-snakken
Forsvarsaktier
Gubra
Hansa Biopharma
ExpreS2ion
AMBU
Amerikanske aktier
GN Store Nord
Smallcap og First North aktier
Grønne Aktier
Politiksnakken
Shipping
Chemometec
Embla Medical
Banker og Finans
Medico
|
3/11 17:02 af Solsen |
Dear mr. Winkel. First of all thanks for an excellent Q3 report ! We recently read in NEJM about a patient who had a remission in NK cell-T-cell lymphoma - fantastic to read. What market potential in this indication could be within reach for Darzalex ?
|
|
3/11 17:01 af Jan Van de Winkel |
and lastly the deal we did with DuoBody and Gilead.
|
|
|
3/11 17:01 af Jan Van de Winkel |
....and the start of recruitment in the Phase 3 ofatumumab multiple sclerosis trials run by Novartis....
|
|
|
3/11 17:00 af Jan Van de Winkel |
....We were also happy to get the Breakthrough designation for dara (the second for daratumumab)....
|
|
|
3/11 17:00 af Jan Van de Winkel |
...and a standard review for dara and Pomalidomide in 3rd line MM ....
|
|
|
3/11 17:00 af Jan Van de Winkel |
The most important developments are the Priority review for Daratumumab with revlimid or with Velcade in second line MM...
|
|
|
3/11 16:59 af Jan Van de Winkel |
....Year to date Darzalex sales 372 mn USD - and royalties of 298 mn DKK to Genmab. Cash at the end of the period 3.9 bn DKK
|
|
|
3/11 16:58 af Jan Van de Winkel |
...Q3 sales for Darzalex 163 mn USD and a 52% increase on Q2....
|
|
|
3/11 16:58 af Jan Van de Winkel |
Financial highlights were revenues 889 up 331 mn DKK or 59%, led by strong Darzalex sales...
|
|
3/11 16:57 af Helge Larsen/PI-redaktør |
Sorry. :-)
|
|
|
3/11 16:57 af Jan Van de Winkel |
As it is Q3 I will focus on that.
|
|
|
3/11 16:57 af Helge Larsen/PI-redaktør |
Genmab has had a great Q2. Can you start with giving us an update on key figures and the most important developments in the Q2 ?
|
|
|
3/11 16:56 af Jan Van de Winkel |
Great to be here. Looking forward to questions.
|
|
|
3/11 16:56 af Helge Larsen/PI-redaktør |
Jan van de Winkel and David Eatwell.
Welcome to the Q & A here on the ProInvestor. We are very happy that you are back in here and ready to answer questions from our investors.
|
|
|
3/11 16:55 af Helge Larsen/PI-redaktør |
Great.
|
|
|
3/11 16:55 af Jan Van de Winkel |
I am here and looking forward to our Q&A session.
|
|
|
3/11 16:50 af Helge Larsen/PI-redaktør |
In 10 minutes we begin the online Q&A with Genmab.
|
|
|
3/11 16:40 af Helge Larsen/PI-redaktør |
This session starts in 20 minutes.
|